Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

PVCT Relative to the S&P 500

PVCT Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Provectus Pharmaceutical Inc (OTCMKT:PVCT) seasonal charts above shows that a Buy Date of December 20 and a Sell Date of March 28 has resulted in a geometric average return of 25.41% above the benchmark rate of the S&P 500 Total Return Index over the past 20 years. This seasonal timeframe has shown positive results compared to the benchmark in 17 of those periods. This is a very good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 20 years by an average of 42.27% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Provectus Biopharmaceuticals Inc is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes (HXs). Its?HX molecule is named rose bengal sodium. The Company’s proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient in the drug product candidates of its current clinical development programs and the preclinical formulations of its current drug discovery programs.

To download PVCT seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: PVCT